Evaluation of transplacental transfer of mRNA vaccine products and functional antibodies during pregnancy and infancy

Mary Prahl (), Yarden Golan, Arianna G. Cassidy, Yusuke Matsui, Lin Li, Bonny Alvarenga, Hao Chen, Unurzul Jigmeddagva, Christine Y. Lin, Veronica J. Gonzalez, Megan A. Chidboy, Lakshmi Warrier, Sirirak Buarpung, Amy P. Murtha, Valerie J. Flaherman, Warner C. Greene, Alan H. B. Wu, Kara L. Lynch, Jayant Rajan and Stephanie L. Gaw ()
Additional contact information
Mary Prahl: University of California
Yarden Golan: University of California
Arianna G. Cassidy: University of California San Francisco
Yusuke Matsui: Gladstone Center for HIV Cure Research, Gladstone Institute
Lin Li: University of California San Francisco
Bonny Alvarenga: University of California
Hao Chen: University of California San Francisco
Unurzul Jigmeddagva: University of California San Francisco
Christine Y. Lin: University of California San Francisco
Veronica J. Gonzalez: University of California San Francisco
Megan A. Chidboy: University of California San Francisco
Lakshmi Warrier: University of California
Sirirak Buarpung: University of California San Francisco
Amy P. Murtha: University of California San Francisco
Valerie J. Flaherman: University of California
Warner C. Greene: Gladstone Center for HIV Cure Research, Gladstone Institute
Alan H. B. Wu: University of California
Kara L. Lynch: University of California
Jayant Rajan: University of California
Stephanie L. Gaw: University of California San Francisco

Nature Communications, 2022, vol. 13, issue 1, 1-12

Abstract: Abstract Studies are needed to evaluate the safety and effectiveness of mRNA SARS-CoV-2 vaccination during pregnancy, and the levels of protection provided to their newborns through placental transfer of antibodies. Here, we evaluate the transplacental transfer of mRNA vaccine products and functional anti-SARS-CoV-2 antibodies during pregnancy and early infancy in a cohort of 20 individuals vaccinated during late pregnancy. We find no evidence of mRNA vaccine products in maternal blood, placenta tissue, or cord blood at delivery. However, we find time-dependent efficient transfer of IgG and neutralizing antibodies to the neonate that persists during early infancy. Additionally, using phage immunoprecipitation sequencing, we find a vaccine-specific signature of SARS-CoV-2 Spike protein epitope binding that is transplacentally transferred during pregnancy. Timing of vaccination during pregnancy is critical to ensure transplacental transfer of protective antibodies during early infancy.

Date: 2022
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-022-32188-1 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:13:y:2022:i:1:d:10.1038_s41467-022-32188-1

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-022-32188-1

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().